STOCK TITAN
  1. Home
  2. News
  3. SLNO

Soleno Therapeutics, Inc. - $SLNO STOCK NEWS

Welcome to our dedicated page for Soleno Therapeutics news (Ticker: $SLNO), a resource for investors and traders seeking the latest updates and insights on Soleno Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Soleno Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Soleno Therapeutics's position in the market.

News
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
Rhea-AI Summary
Soleno Therapeutics, Inc. announced the appointments of key executives and advisors, including Meredith Manning as Chief Commercial Officer, Dairine Dempsey as Vice President, Europe, and Lauren Budesheim as Vice President of Human Resources. The company also appointed key advisors Shamim Ruff and James Geraghty. The new team brings extensive industry experience and expertise in global commercialization, regulatory affairs, and human resources. The appointments aim to strengthen capabilities in the U.S. and Europe as the company advances its DCCR therapy towards NDA and MAA filings for potential approval in Prader-Willi Syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
management
-
News
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Soleno Therapeutics, Inc. (SLNO) announced the grant of inducement awards to three new employees, with 102,500 non-qualified stock options at an exercise price of $36.70 per share, vesting over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
News
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Soleno Therapeutics, Inc. (NASDAQ: SLNO) announces the grant of inducement awards to two new employees. The Compensation Committee approved the grant of non-qualified stock options to purchase 145,000 shares of common stock at an exercise price of $21.93 per share. The options will vest over a four-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Soleno Therapeutics, Inc. reported positive statistically significant top-line data from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR for the treatment of Prader-Willi syndrome. Soleno's cash and cash equivalents were approximately $52.4 million as of September 30, 2023. They received gross proceeds of $169.9 million from recent financing activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
earnings
-
News
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome
Rhea-AI Summary
Soleno Therapeutics, Inc. has published one-year results from the Phase 3 DESTINY PWS study and the open-label extension period of Study C602, evaluating DCCR tablets for patients with Prader-Willi syndrome (PWS). The study showed significant improvements in hyperphagia and other behavioral complications in participants. Soleno plans to submit an NDA to the FDA for DCCR in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
News
Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
Rhea-AI Summary
Soleno Therapeutics to present at FPWR Research Symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.15%
Tags
none
News
Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
Rhea-AI Summary
Soleno Therapeutics announces oral presentation at FPWR 2023 Research Symposium on results from Study C602 for the treatment of Prader-Willi syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.15%
Tags
none
-
News
Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
Soleno Therapeutics closes public offering, raising $69.0 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
offering
-
News
Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
Rhea-AI Summary
Soleno Therapeutics, Inc. announces pricing of underwritten public offering of 3,000,000 shares of common stock at $20.00 per share, expected to raise approximately $60.0 million. Underwriters granted 30-day option to purchase up to 450,000 additional shares. Concurrent private placement with existing investors for up to approximately $60.0 million. Closing expected on or about October 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.48%
Tags
offering
News
Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
Rhea-AI Summary
Soleno Therapeutics, Inc. plans to offer and sell shares of its common stock and/or pre-funded warrants in a public offering. The underwriters have an option to purchase additional shares equal to 15% of the offering. The company also intends to enter into a securities purchase agreement for up to $30 million of shares. Guggenheim Securities, Cantor Fitzgerald & Oppenheimer are acting as book-running managers. The offering is subject to market conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.48%
Tags
offering
Stock SLNO logo
Soleno Therapeutics, Inc.

Nasdaq:SLNO

SLNO Rankings

#2042 Ranked by Market Cap
#1 Ranked by Stock Gains
N/A Ranked by Dividends

SLNO Stock Data

1.64B
13.17M
2.06%
97.44%
8.5%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About SLNO

soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.